PEDIATRIC ATOPIC DERMATITIS | LEO LP0162 | PHASE III

Status: FULLY RECRUITED

Drug: Tralokinumab

Timeline: 29 visits in 52 weeks

Detailed Description

This is a randomized, double-blinded, placebo-controlled trial in adolescent subjects aged 12 to 17 years with moderate to severe atopic dermatitis.

Inclusion

• Informed consent
• Age 12 to 17 years old
• Body Weight at baseline >= 30 kg
• Diagnosis of AD for more than 1 year with >=10% BSA involvement
• Prior use and failure of topical corticosteroid treatment
• Male or Female

Exclusions

• Current participation in any other interventional trial
• Prior participation in a Tralokinumab trial
• Significant medical history
• Female subjects who are pregnant or lactating

If you’re interested in participating, please SEND US AN EMAIL AND/OR CONTACT US and our research team will be in touch.